ClinicalTrials.gg
Not yet recruitingNCT07438262AminoECMOUpdated Feb 27, 2026

The AminoECMO Pilot Trial

A Phase 2 interventional study of Synthamin-17 (10% amino acid solution) and Placebo (Hartmann's balanced crystalloid solution) in Acute Kidney Injury, sponsored by Australian and New Zealand Intensive Care Research Centre. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Australian and New Zealand Intensive Care Research Centre · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Acute Kidney Injury with a site in Australia — 3 open to participants now, 4 under way, none of them phase 3. Acute Kidney Injury · Australia.

Planned enrollment
15th of 18
40 · median 208
Started
2026
with 1 other
Phase 2
6 of 23
1 open now
Registered
22nd of 23
by date
Lead sponsor
1 of 23
Australian and New Zealand Intensive Care Research Centre

Among the 23 studies in Acute Kidney Injury with a site in Australia, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 in phase 2, and was the 22nd registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

3 of the 23 studies in Acute Kidney Injury with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Acute Kidney Injury with a site in Australia, or all of them as a file.
02

Study summary

Acute kidney injury (AKI) is a serious problem for patients in intensive care, especially those on life-support machines like ECMO (which helps the heart and lungs). More than half of these patients develop severe kidney problems that often require dialysis, and this greatly increases the risk of poor outcomes.

Doctors try to prevent AKI by treating the underlying illness, avoiding kidney-harming drugs, and carefully managing fluids. But these methods are mostly supportive - they don't actively improve kidney function.

Studies in surgical patients (especially heart and urology operations) show that giving amino acids before surgery can reduce the chance of developing AKI. A major clinical trial even found that this approach significantly lowered AKI rates in heart surgery patients.

Amino acids (the building blocks of protein) seem to boost kidney performance. When given through a drip or feeding tube, they increase blood flow to the kidneys and may "wake up" unused kidney capacity - a concept called "functional renal reserve." It's not yet clear whether amino acids help critically ill patients on ECMO. More research is needed to see if this promising strategy can improve kidney function and outcomes in the sickest patients.

Read the detailed description

Acute kidney injury (AKI) is common in critically ill patients, especially in those requiring extracorporeal membrane oxygenation (ECMO). AKI is associated with significant morbidity and mortality. The current management for the prevention of AKI is supportive, such as treating underlying causes, avoiding nephrotoxins, and optimising fluid status. Despite optimal care, more than half of ECMO patients develop severe AKI requiring renal replacement therapy (RRT), including 46% in venovenous (V-V) ECMO, and 61% in venoarterial (V-A) ECMO. Severe AKI is associated with significantly worse outcomes and higher mortality, and there is a strong need to identify therapies that can improve renal function in ECMO.

It has already been established that glomerular filtration rate (GFR) increases in response to (IV or enteral) protein administration. The precise mechanism for increased GFR is not completely understood, however recruitment of dormant renal function (called functional renal reserve RFR) has been hypothesised. Amino acid delivery is associated with a renal vasodilation mediated increase renal blood flow by >30%. Different metabolic, endocrine, and paracrine factors have been implicated. It has been suggested that recruitment of RFR could prevent or manage AKI.

Amino Acids Infusions and Preventing AKI The impact of amino acids on renal function has been investigated in clinical trials. This has predominantly occurred in the perioperative setting, in patients with stable renal function undergoing operations associated with a significant risk of developing an AKI. In cardiac surgery, several early-phase studies have demonstrated an improvement in measures of renal function with the perioperative infusion of amino acids. These findings are not isolated to the cardiac surgery population, which may have unique pathological mechanisms for AKI, as a recent pilot RCT in patients undergoing major urology surgery demonstrated a reduction in the incidence of postoperative AKI. Recently a large RCT published in the New England Journal of Medicine showed that the peri-operative administration of amino acids in patients undergoing cardiac surgery significantly decreased the incidence of AKI. Importantly, in a sub group analysis of 232 patients who underwent perioperative mechanical cardiac support, the rate of AKI was lower in the group randomized to amino acids: 44.6 vs 60.8% relative risk 0.73 (0.57-0.94 P=0.01 NNT =6) suggesting a potentially important benefit in this group.

Despite the increasing interest and quantity of research surrounding the association between amino acid infusion and kidney function, several unanswered questions remain. Firstly, although amino acid infusion has been demonstrated to reduce the incidence of AKI when administered before an insult, the impact on renal function in critically ill patients receiving ECMO therapy is unclear, particularly as the insult may have already started to occur prior to ECMO initiation. Secondly, several recent studies of high dose protein have suggested potential harm in patients randomised to a higher dose of protein (2.2g/kg/day vs \<1.2g/kg/day) when given over prolonged periods.

The intervention in this pilot differs as it is will commence \<24hours post ECMO initiation, and it is given short term only (up to 48 hours). It remains unclear if this will translate to improve renal and patient outcomes.

In summary, ECMO therapy is associated with an increased risk of acute kidney injury. The current management for prevention of AKI is supportive with no current therapies that can decrease the risk of AKI and improve clinical outcomes. Given the physiologically and clinically demonstratable impact of amino acid infusion on renal function, further research is logical and desirable.

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • Acute kidney injury
  • Extracorporeal Membrane Oxygenation
  • Amino Acids
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years
  • Enrolled in the EXCEL Registry

Exclusion criteria

Exclusion Criteria:

  • Urea level ≥30 mmol/L
  • Requirement for renal replacement therapy
  • Chronic hemodialysis or peritoneal dialysis
  • ECMO for ≥24 hours
  • Pre-admission CKD with an \<30 ml/min
  • Previous enrolment in this study
  • Pregnant or Lactating
  • Known to AA infusion
  • ECMO expected to cease ≤24 hours
  • Expected to be transferred to another hospital ≤24 hours
  • Treating clinical team deems study is not in the patient's best interest
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Intervention Arm - Synthamin-17 electrolyte-free solution

    The study drug within the intervention arm will be continually infused for up to 48 hours whilst the patient is on ECMO. The infusion rate will be set to 2g/kg/ideal body weight/day (to a maximum of 100g). Patients enrolled into the control arm will be continually infused with a placebo for up to 48 hours whilst on ECMO.

    Dietary Supplement: Synthamin-17 (10% amino acid solution)

  • Placebo comparator
    Control Arm - Hartmann's balanced crystalloid solution

    Participants allocated to the control group will receive placebo comprised of Hartmann's balanced crystalloid solution (compound sodium lactate) to a maximum of 500mls and 48-hours.

    Other: Placebo (Hartmann's balanced crystalloid solution)

Interventions

  • Dietary supplementAmino-acid, glucose, and electrolyte solutionStudies of Amino-acid, glucose, and electrolyte solutionAmino-acid, glucose, and electrolyte solution pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    First time comparing amino acid to placebo for prevention of acute kidney injury in patients receiving extracorporeal membrane oxygenation

  • OtherPlacebo (Hartmann's balanced crystalloid solution)

    Participants allocated to the control group will receive placebo comprised of Hartmann's balanced crystalloid solution (compound sodium lactate) to a maximum of 500mls and 48-hours.

06

What researchers measure

Primary outcomes

  1. The number of patients who received AA infusion within 24 hours of being randomised in the trial after ECMO initiation.

    Participants randomised to the Intervention Group who received AA infusion within the 24 hour study time frame.

    Time frame: 24 Hours from randomisation

Secondary outcomes

  1. Number of hours post randomisation that AA infusion was commenced in the intervention group

    Date and time of randomisation and date and time that AA infusion was commenced

    Time frame: Up to 24 hours post randomisation, or will be recorded as a Protocol Deviation

Other outcomes

  1. Number of patients who received AA infusion in the Intervention Group

    The total number of participants randomised to the Intervention Group who received AA infusion

    Time frame: Up to 48 hours from randomisation

  2. Number of patients who received placebo in the control group

    The number of participants randomised to the Control Group who received placebo

    Time frame: Up to 48 hours post randomisation

  3. Mean duration of AA infusion

    What was the mean duration of AA infusion in participants who received it?

    Time frame: Up to 48 hours post randomisation

  4. Enrolment Rate

    How many participants were enrolled in the trial from the eligible population?

    Time frame: Up to 7 days from commencement of ECMO

  5. Number of Protocol Deviations

    How many total Protocol Deviations were recorded?

    Time frame: Up to 7 days post commencement of ECMO

  6. Mortality - in ICU and in hospital

    Patients who died before being discharged from ICU or Hospital

    Time frame: Participants discharge from ICU and Hospital

  7. Urine output measured over 48 hours post the start of the AA or placebo infusion

    Hourly urine output measures

    Time frame: From initiation of AA or placebo infusion

  8. Serum creatinine measured over 48 hours post the start of the AA and placebo infusion

    Serum creatinine measures from bloods taken at specified times

    Time frame: Blood sampling at Baseline, Day 1, Day 3, and Day 7

  9. Urinary Neutrophil Gelatinase-associated lipocalin (NGAL) measured over 48 hours post the start of the AA and placebo infusion

    Urinary NGAL processed from urine samples at pre-specified times

    Time frame: Urine sampling taken at Baseline, Day 1, Day 3, and Day 7

  10. Urine albumin/creatinine ratio (ACR) measured over 48 hours post the start of the AA and placebo infusion

    ACR processed from urine samples collected at pre-specified times

    Time frame: Urine sampling at Baseline, Day 1, Day 3, and Day 7

  11. Urinary electrolytes measured over 48 hours post the start of the AA and placebo infusion

    Urinary electrolytes processed from samples taken at pre-specified times

    Time frame: Urine sampling at Baseline, Day 1, Day 3, and Day 7

  12. Maximum severity of AKI up to day 7 (defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria)

    The KDIGO will be assessed from serum creatinine and urine output

    Time frame: Assessed at Day 1, Day 3, and Day 7 from randomisation

  13. Duration of Acute Kidney Injury (AKI)

    If AKI is present how long does it persist?

    Time frame: Up to Day 30 post randomisation

  14. Occurrence of acute kidney disease (AKD) (defined by the Acute Dialysis Quality Initiative - ADQI criteria)

    Calculation of ADQI from serum creatinine, urine output and glomerular filtration rate

    Time frame: Up to Day 7 from randomisation

  15. New onset renal replacement therapy (RRT) during ECMO

    Was RRT commenced for AKI while participant was receiving ECMO?

    Time frame: From randomisation to cessation of ECMO flow

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The management committee support the view of the international committee of medical journal editors and the world health organisation (WHO) with reference to the ethical obligation to responsibly share data acquired by interventional clinical trials. At the conclusion of the study, the management committee will consider requests from researchers who provide a methodically sound confidential scientific proposal as per the data sharing policy set out in the ANZIC-RC terms of reference. Only de-identified data will be shared and all requests for data must comply with the ethical, regulatory, and legislative requirements governing their jurisdiction.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Supporting information will be available from October 2026, and there will be no specified end date that this information can be accessed.

Access criteria: The Study Protocol and Statistical Analysis Plan will both be available on the Monash ANZIC-RC site from October 2026 onward.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Aug 2027, 18 months later.

Of 39 non-industry phase 2 interventional studies under Acute Kidney Injury, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 42. This study's planned 18 months is below that.

Counting every sponsor, half of 57 studies reached it within 29 months; a quarter within 16 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 27, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07438262
Lead sponsor
Australian and New Zealand Intensive Care Research Centre
Collaborators
Monash University, The Alfred
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Aug 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Aidan Burrell, MBBS, FCICM, DDU, PhD
Contact
aidanburrell@gmail.com
+61 422 848 716
Stephanie M Hunter, BN, PhD
Contact
Stephanie.Hunter@monash.edu
+61 422 033 612
Carol Hodgson, FAHMS
study chair · Monash University, School of Public Health and Preventative Medicine, ANZIC-RC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amino-acid, glucose, and electrolyte solution

Start the discussion